Fludarabine (injection): Difference between revisions

Jump to navigation Jump to search
m (Protected "Fludarabine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +))
Line 23: Line 23:
}}
}}
{{SI}}
{{SI}}
{{EH}}
 


==Overview==
==Overview==
Line 51: Line 51:


{{Chemotherapeutic agents}}
{{Chemotherapeutic agents}}
{{SIB}}
 
[[Category:Organofluorides]]
[[Category:Organofluorides]]
[[Category:Chemotherapeutic agents]]
[[Category:Chemotherapeutic agents]]

Revision as of 02:46, 9 August 2012

Fludarabine (injection)
Clinical data
Pregnancy
category
  • D
Routes of
administration
Intravenous, oral
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability55%
Protein binding19 to 29%
Elimination half-life20 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC10H13FN5O7P
Molar mass365.212 g/mol

WikiDoc Resources for Fludarabine (injection)

Articles

Most recent articles on Fludarabine (injection)

Most cited articles on Fludarabine (injection)

Review articles on Fludarabine (injection)

Articles on Fludarabine (injection) in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Fludarabine (injection)

Images of Fludarabine (injection)

Photos of Fludarabine (injection)

Podcasts & MP3s on Fludarabine (injection)

Videos on Fludarabine (injection)

Evidence Based Medicine

Cochrane Collaboration on Fludarabine (injection)

Bandolier on Fludarabine (injection)

TRIP on Fludarabine (injection)

Clinical Trials

Ongoing Trials on Fludarabine (injection) at Clinical Trials.gov

Trial results on Fludarabine (injection)

Clinical Trials on Fludarabine (injection) at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Fludarabine (injection)

NICE Guidance on Fludarabine (injection)

NHS PRODIGY Guidance

FDA on Fludarabine (injection)

CDC on Fludarabine (injection)

Books

Books on Fludarabine (injection)

News

Fludarabine (injection) in the news

Be alerted to news on Fludarabine (injection)

News trends on Fludarabine (injection)

Commentary

Blogs on Fludarabine (injection)

Definitions

Definitions of Fludarabine (injection)

Patient Resources / Community

Patient resources on Fludarabine (injection)

Discussion groups on Fludarabine (injection)

Patient Handouts on Fludarabine (injection)

Directions to Hospitals Treating Fludarabine (injection)

Risk calculators and risk factors for Fludarabine (injection)

Healthcare Provider Resources

Symptoms of Fludarabine (injection)

Causes & Risk Factors for Fludarabine (injection)

Diagnostic studies for Fludarabine (injection)

Treatment of Fludarabine (injection)

Continuing Medical Education (CME)

CME Programs on Fludarabine (injection)

International

Fludarabine (injection) en Espanol

Fludarabine (injection) en Francais

Business

Fludarabine (injection) in the Marketplace

Patents on Fludarabine (injection)

Experimental / Informatics

List of terms related to Fludarabine (injection)


Overview

Fludarabine (marketed as fludarabine phosphate under the trade name Fludara) is a chemotherapy drug used in the treatment of hematological malignancies.

Indications

Fludarabine is highly effective in the treatment of chronic lymphocytic leukemia, producing higher response rates than alkylating agents such as chlorambucil alone.[1] Fludarabine is used in various combinations with cyclophosphamide, mitoxantrone, dexamethasone and rituximab in the treatment of indolent non-Hodgkins lymphomas. As part of the FLAG regimen, fludarabine is used together with cytarabine and granulocyte colony-stimulating factor in the treatment of acute myeloid leukaemia. Because of its immunosuppressive effects, fludarabine is also used in some conditioning regimens prior to non myeloablative allogeneic stem cell transplant.

Pharmacology

Fludarabine is a purine analog, and can be given both orally and intravenously. Fludarabine inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase. It is active against both dividing and resting cells.

Side effects

Fludarabine is associated with profound lymphopenia, and as a consequence, increases the risk of opportunistic infections significantly. Patients who have been treated with fludarabine will usually be asked to take co-trimoxazole or to use monthly nebulised pentamidine to prevent Pneumocystis jiroveci pneumonia. The profound lymphopenia caused by fludarabine renders patients susceptible to transfusion-associated graft versus host disease, a fatal complication of blood transfusion. For this reason, all patients who have ever received fludarabine should only be given irradiated blood components.

Fludarabine causes anemia, thrombocytopenia and neutropenia, requiring regular blood count monitoring. Some patients require blood and platelet transfusion, or G-CSF injections to boost neutrophil counts.

Fludarabine is associated with the development of severe autoimmune hemolytic anemia in a proportion of patients.[2]

Difficulties are often encountered when harvesting peripheral blood stem cells from patients previously treated with fludarabine.[3]

References

  1. Rai KR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-7. PMID 11114313
  2. Gonzalez H et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther. 1998;40:113-8. PMID 9698219
  3. Tournilhac O et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004;103:363-5. PMID 12969985

External links

Template:WH Template:WikiDoc Sources